Ongoing developments in RSV prophylaxis: a clinician's analysis

Area of Science:

• Virology
• Immunology
• Public Health

Background:

• Respiratory syncytial virus (RSV) is a leading cause of infant hospitalization and a significant cause of morbidity in the elderly and immunocompromised.
• RSV infections can lead to long-term respiratory issues, including recurrent wheezing and asthma diagnoses.
• Despite decades of research, effective pharmacological treatments are lacking, with supportive care remaining the primary management strategy.

Purpose of the Study:

• To review current prophylactic options for RSV.
• To summarize the status of ongoing RSV vaccine clinical trials.
• To discuss various vaccine development strategies and identify major hurdles.

Main Methods:

• Literature review of existing RSV prophylactic measures.
• Analysis of current RSV vaccine development pipelines (preclinical to Phase III).
• Discussion of diverse vaccine strategies and developmental challenges.

Main Results:

• Palivizumab is the sole available RSV prophylaxis, with limited efficacy and high cost, restricting its use to high-risk infants.
• Multiple RSV vaccine candidates are in various stages of clinical development, employing diverse strategies.
• Past vaccine trials, like the formalin-inactivated RSV vaccine, highlight the complexities and risks involved in RSV vaccine development.

Conclusions:

• There is an urgent need for effective RSV vaccines due to the virus's widespread impact.
• Ongoing clinical trials represent promising avenues for RSV prevention.
• Overcoming developmental hurdles is crucial for achieving a safe and broadly effective RSV vaccine.